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Objectives. This study sought to evaluate the preventive effect of
vitamin C, an antioxidant, on the development of nitrate toler-
ance.
Background. Decreased intracellular production of cyclic
guanosine monophosphate (cGMP) is a mechanism of nitrate
tolerance, and increased superoxide levels and reduced activation
of guanylate cyclase have been observed in vitro.
Methods. In this double-blind, placebo-controlled study, 24
normal volunteers and 24 patients with ischemic heart disease
(IHD) were randomized to receive either vitamin C (2 g three
times daily [vitamin C group, n 5 12]) or placebo (placebo group,
n 5 12). The vasodilator response to nitroglycerin was assessed
with forearm plethysmography by measuring the change in FBF
before and 5 min after sublingual administration of 0.3 mg of
nitroglycerin. Blood samples were simultaneously obtained to
measure platelet cGMP levels. FBF was measured, and blood
sampling was performed serially at baseline (day 0), 3 days after
administration of vitamin C or placebo (day 3) and 3 days after
application of a 10-mg/24-h nitroglycerin tape concomitantly with
oral vitamin C or placebo (day 6).
Results. There were no differences between the vitamin C and
placebo groups in percent increases in FBF (%FBF) or platelet
cGMP levels (%cGMP) after administration of sublingual nitro-
glycerin on day 0 (%FBF: normal volunteers 31 6 8 vs. 32 6 10;
patients with IHD 32 6 9 vs. 32 6 8; %cGMP: normal volunteers
37 6 9 vs. 39 6 10; patients with IHD 38 6 10 vs. 39 6 10 [vitamin
C group vs. placebo group]) or day 3 (%FBF: normal volunteers
32 6 9 vs. 33 6 9; patients with IHD 31 6 10 vs. 31 6 10; %cGMP:
normal volunteers 36 6 8 vs. 37 6 9; patients with IHD 39 6 11
vs. 38 6 10 [vitamin C group vs. placebo group]). The %FBF and
%cGMP in the placebo group were significantly lower on day 6
than in the vitamin C group (%FBF: normal volunteers 30 6 8 vs.
19 6 4, p < 0.01; patients with IHD 29 6 9 vs. 17 6 6, p < 0.01;
%cGMP: normal volunteers 36 6 10 vs. 17 6 6, p < 0.01; patients
with IHD 37 6 11 vs. 15 6 5, p < 0.01 [vitamin C group vs.
placebo group]).
Conclusions. These results indicate that combination therapy
with vitamin C is potentially useful for preventing the develop-
ment of nitrate tolerance.
(J Am Coll Cardiol 1998;31:1323–9)
©1998 by the American College of Cardiology
Organic nitrates are widely used in cardiovascular medicine,
but their continuous administration can result in the rapid
development of tolerance (1,2). The underlying mechanisms
responsible for nitrate tolerance are probably multifactorial (3)
and may include neurohormonal counterregulatory mechanisms
(4), intravascular volume expansion (5) or intrinsic abnormal-
ities, such as desensitization of the target enzyme guanylate
cyclase (6) or a decrease in nitroglycerin biotransformation (7).
Recent experimental data (8) have demonstrated that ni-
trate tolerance is associated with increased vascular superoxide
anion production. These radicals may inactivate the enzymes
involved in the release of nitric oxide from nitroglycerin,
leading to impaired cyclic guanosine monophosphate (cGMP)
production and tolerance. A more recent study (9) showed that
tolerance was associated with an enhanced propensity for
vasoconstriction secondary to increased endothelin expression
within the vascular smooth muscle. Vitamin C is known to be
the most important endogenous water-soluble antioxidant, and
the resistance of low density lipoprotein to oxidation is in-
creased by oral intake of vitamin C (10). We recently reported
(11) the preventive effect of intravenous administration of
vitamin C on the development of nitrate tolerance in patients
with congestive heart failure. We also reported (12) the
preventive effect of oral supplemental vitamin E on the
development of nitrate tolerance in normal subjects and
patients with ischemic heart disease (IHD).
Therefore, the present study was designed to investigate the
effect of oral supplemental vitamin C, an antioxidant, on
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nitrate tolerance during continuous administration of nitro-
glycerin in normal subjects and in patients with IHD.
Methods
Patients. The study included 24 normal volunteers (18
men, 6 women; 19 to 38 years old) and 24 patients with IHD
(19 men, 5 women; 46 to 77 years old). The present study
includes the same normal volunteers as those in our previous
report (12). The normal volunteers had no history of renal or
cardiac disease, and none had been exposed to any nitrate
compounds or cardiac medications. Of the patients with IHD,
15 had received long-acting nitrates (isosorbide dinitrate re-
tard [ISDN-Retard], 20 mg twice a day), and 12 had received
calcium channel blocking agents. Long-acting nitrates were
discontinued 72 h before the study. Other medications were
continued throughout the study. The clinical characteristics of
the study subjects are shown in Table 1.
Study protocol. We measured the vasodilator response to
sublingual nitroglycerin by plethysmography and platelet
cGMP at baseline (day 0), after 3 days of administration of
vitamin C or placebo (day 3) and after 3 days of the application
of a 10-mg/24-h nitroglycerin tape concomitantly with oral
vitamin C or placebo (day 6). An 18-gauge heparin lock was
inserted in the contralateral forearm to allow venous blood
sampling for measurements of platelet cGMP levels.
The protocol of the present study is shown in Figure 1 and
is the same protocol used in our previous study (12). Baseline
forearm blood flow (FBF) was recorded by plethysmography
before and 5 min after administration of 0.3 mg of sublingual
nitroglycerin on day 0. Normal volunteers and patients with
IHD were then randomized by a double-blind, parallel-design
to receive either 2 g three times daily of vitamin C (vitamin C
group, n 5 12) or placebo three times daily (placebo group,
n 5 12). Subjects returned 3 days after treatment with vitamin
C or placebo for measurements of FBF and platelet cGMP
levels before and after administration of sublingual nitroglyc-
erin. A 5-mg nitroglycerin tape (Millisrol Tape, Nippon Kay-
aku, Tokyo, Japan) was then applied twice a day. Final
measurements were obtained 3 days after treatment with
combined continuous transdermal nitroglycerin and vitamin C
or placebo.
The study protocol was approved by the ethics committee of
Tsukuba University, Tsukuba, Japan, and written informed
consent for participation in this study was obtained from all
subjects.
Assessment of vasodilator response to nitroglycerin. To
evaluate the vasodilator response to nitroglycerin, FBF was
measured with a mercury in Silastic strain gauge plethysmo-
graph and the venous occlusion technique. The strain gauge
was placed 5 cm below the antecubital crease and connected to
a calibrated plethysmograph. FBF is expressed as the rate of
change in forearm volume (ml/min per 100 ml forearm). The
pressure in the venous occlusion or congesting cuff was
40 mm Hg. Circulation to the hand was arrested during
determinations of FBF by inflation of a cuff around the wrist to
10-mm Hg suprasystolic pressure. We used the average of
three measurements made at 15-s intervals to represent FBF.
Preparation of platelet cGMP. Blood samples were drawn
into syringes containing 5 mmol/liter EDTA and a cGMP phos-
phodiesterase inhibitor (1023 mol/liter 2-O-propoxyphenyl-8-
azapurin-6-one dissolved in 1% triethanolamine). Platelet-rich
and platelet-poor plasma were prepared immediately after
blood sampling by centrifugation at 200 g for 20 min. Platelet-
rich plasma was further centrifuged at 2,500 g for 10 min, and
the supernatant was discarded. The pellet was suspended in
Abbreviations and Acronyms
cGMP 5 cyclic guanosine monophosphate
FBF 5 forearm blood flow
IHD 5 ischemic heart disease
%FBF 5 percent increase in forearm blood flow
%cGMP 5 percent increase in cyclic guanosine monophosphate
Table 1. Clinical Characteristics of Study Subjects
Normal Volunteers Patients With IHD
Placebo Group
(n 5 12)
Vitamin C Group
(n 5 12)
Placebo Group
(n 5 12)
Vitamin C Group
(n 5 12)
Age (yr) 36 6 8 32 6 6 65 6 10 64 6 8
Men/women 9/3 9/3 10/2 9/3
Smokers 5 (42%) 4 (33%) 8 (67%) 9 (75%)
Mean blood pressure (mm Hg) 110 6 15 114 6 16 141 6 12 138 6 16
Pulse rate (beats/min) 72 6 4 68 6 4 77 6 5 75 6 7
Total cholesterol (mg/dl) 184 6 16 183 6 15 211 6 16 208 6 15
Data are expressed as number (%) of subjects or mean value 6 SD. IHD 5 ischemic heart disease.
Figure 1. Study protocol. NTG 5 nitroglycerin; t.i.d. 5 three times
daily. *Plethysmography and blood sampling.
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modified Tyrode’s solution (containing 0.35% bovine serum
albumin and 5 mM HEPES, pH 7.35) to obtain a final platelet
count of 2 to 3 3 106 platelets/ml. The samples were stored
frozen at 270°C until analysis (13).
Platelet cGMP Assay. Trichloroacetic acid (0.5 ml in a final
concentration of 6%) was added to 1 ml of the platelet
preparation. After centrifugation at 2,500 g for 20 min, trichlo-
roacetic acid was extracted four times from the supernatant
with water-saturated ether. The aqueous phase was then
assayed for cGMP using a commercially available radioimmu-
noassay kit (Yamasa Shoyu, Choshi, Japan) (14). The results
are expressed in picomoles per 109 platelets. The coefficients of
variation averaged 3.4% for intraassay error and 11.9% for
interassay error.
Statistical analysis. Results are expressed as mean value 6
SD for FBF and as mean value 6 SEM for platelet cGMP
levels. Differences among the test days were analyzed by
repeated measures analysis of variance with the Bonferroni
test, and differences between before and after sublingual
nitroglycerin were analyzed by the Student t test. A p level ,
0.05 was accepted as statistically significant.
Results
FBF. Figure 2 shows the change in FBF before and after
sublingual nitroglycerin in the normal volunteers and in pa-
tients with IHD. FBF (ml/min per 100 ml forearm) after
sublingual nitroglycerin was increased both on day 0 (vitamin C
group: normal volunteers 2.62 6 0.55 to 3.44 6 0.66; patients
with IHD 2.54 6 0.48 to 3.36 6 0.56; placebo group: normal
volunteers 2.63 6 0.65 to 3.46 6 0.64; patients with IHD
2.59 6 0.64 to 3.4 6 0.69) and on day 3 (vitamin C group:
normal volunteers 2.64 6 0.52 to 3.48 6 0.71; patients with
IHD 2.58 6 0.48 to 3.37 6 0.51; placebo group: normal
volunteers 2.61 6 0.63 to 3.46 6 0.71; patients with IHD
2.64 6 0.52 to 3.46 6 0.61). There was no significant difference
in FBF before and after nitroglycerin between the two groups
in the normal volunteers and patients with IHD.
On day 6 (after 3 days of the application of a 10-mg/24-h
nitroglycerin tape concomitantly with oral vitamin C or place-
bo), FBF (ml/min per 100 ml forearm) in the placebo group
was increased from 2.61 6 0.61 to 3.11 6 0.77 in normal
volunteers and from 2.56 6 0.72 to 2.98 6 0.73 in patients with
IHD after sublingual administration of nitroglycerin. However,
the flow after sublingual nitroglycerin was significantly lower
than that at days 0 and 3. By contrast, in the vitamin C group,
the change in FBF after sublingual administration of nitroglyc-
erin was similar to the change on days 0 and 3 (normal
volunteers 2.63 6 0.68 to 3.41 6 0.81; patients with IHD
2.61 6 0.72 to 3.38 6 0.79). FBF after sublingual nitroglycerin
in the vitamin C group was significantly greater than that in the
placebo group in normal volunteers (p , 0.05) and in patients
with IHD (p , 0.05).
The percent increase in FBF (%FBF) after sublingual
administration of nitroglycerin is shown in Figure 3.
There was no significant difference on days 0 and 3 between
the placebo group and the vitamin C group (day 0: vitamin C
group, normal volunteers 31 6 8%; patients with IHD 32 6
9%; placebo group, normal volunteers 32 6 10%; patients with
IHD 32 6 8% and day 3: vitamin C group, normal volunteers
32 6 9%; patients with IHD 31 6 10%; placebo group, normal
volunteers 33 6 9%; patients with IHD 31 6 10%).
On day 6 (after 3 days of the application of a 10-mg/24-h
nitroglycerin tape concomitantly with oral vitamin C or place-
bo), the %FBF in the placebo group (normal volunteers 19 6
4%; patients with IHD 17 6 6%) was significantly reduced
compared with that on days 0 and 3 (p , 0.01). By contrast, in
the vitamin C group, %FBF after nitroglycerin (normal volun-
teers 30 6 8%; patients with IHD 29 6 9%) was maintained on
day 6, and it was significantly greater than that in the placebo
group (p , 0.01).
Platelet cGMP Level. Levels of platelet cGMP before and
after sublingual administration of nitroglycerin are shown in
Figure 4. In the present study, levels of platelet cGMP in the
patients with IHD were significantly lower than those in the
Figure 2. FBF before (open circles [vitamin C group] and open
squares [placebo group]) and after sublingual nitroglycerin (solid
circles [vitamin C group] and solid squares [placebo group]) in normal
volunteers (left) and patients with IHD (right). Data shown are mean
value 6 SD. *p , 0.05 versus days 0 and 3.
Figure 3. Percent increase in FBF after sublingual ni-
troglycerin in normal volunteers (left) and patients with
IHD (right). Open bars 5 placebo group; solid bars 5
vitamin C group. Data shown are mean value 6 SD.
*p , 0.01 versus days 0 and 3.
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normal volunteers in the two groups on all testing days (p ,
0.05).
Levels of platelet cGMP (pmol/109 platelets) in normal
volunteers were significantly increased after sublingual admin-
istration of nitroglycerin on day 0 (vitamin C group 0.60 6 0.05
to 0.82 6 0.05; placebo group 0.62 6 0.05 to 0.86 6 0.05) and
on day 3 (vitamin C group 0.61 6 0.04 to 0.83 6 0.05; placebo
group 0.62 6 0.05 to 0.83 6 0.05). There was no significant
difference between the two groups on days 0 and 3. Platelet
cGMP levels in patients with IHD were also increased after
sublingual administration of nitroglycerin on day 0 (vitamin C
group 0.36 6 0.03 to 0.50 6 0.04; placebo group 0.37 6 0.05 to
0.51 6 0.04) and on day 3 (vitamin C group 0.37 6 0.06 to
0.51 6 0.04; placebo group 0.36 6 0.05 to 0.50 6 0.06). There
was no significant difference between the two groups on days 0
and 3.
On day 6 (after 3 days of the application of a 10-mg/24-h
nitroglycerin tape concomitantly with oral vitamin C or place-
bo), platelet cGMP levels before nitroglycerin were signifi-
cantly lower in the placebo group than those on days 0 and 3
(normal volunteers 0.48 6 0.05, p , 0.05 vs. day 0 and day 3;
patients with IHD 0.21 6 0.03, p , 0.05 vs. day 0 and day 3).
Platelet cGMP levels after sublingual nitroglycerin were also
significantly lower (normal volunteers 0.56 6 0.06, p , 0.05 vs.
day 0 and day 3; patients with IHD 0.24 6 0.04, p , 0.05 vs. day
0 and day 3). In the vitamin C group, platelet cGMP levels on
day 6 were increased from 0.61 6 0.05 to 0.83 6 0.06 in normal
volunteers and from 0.36 6 0.04 to 0.49 6 0.06 in patients with
IHD after sublingual nitroglycerin. There was no significant
difference in the platelet cGMP levels in the vitamin C group
among the testing days, and levels were significantly higher
than those of the placebo group (p , 0.05).
The percent increase in platelet cGMP (%cGMP) after
sublingual administration of nitroglycerin is shown in Figure 5.
On day 0 and day 3, there was no difference between the
placebo group and the vitamin C group (day 0: vitamin C
group, normal volunteers 37 6 9%; patients with IHD 38 6
10%; placebo group, normal volunteers 39 6 10%; patients
with IHD 39 6 10% and day 3: vitamin C group, normal
volunteers 36 6 8%; patients with IHD 39 6 11%; placebo
group, normal volunteers 37 6 9%; patients with IHD 38 6
10%).
On day 6 (after 3 days of the application of a 10-mg/24-h
nitroglycerin tape concomitantly with oral vitamin C or place-
bo), %cGMP in the placebo group (normal volunteers 17 6
7%; patients with IHD 15 6 5%) was significantly lower than
that on day 0 and day 3 (p , 0.01). By contrast, in the vitamin
C group, %cGMP was maintained on day 6 (normal volunteers
36 6 10%; patients with IHD 37 6 11%) and was significantly
greater than that in the placebo group (p , 0.01).
Discussion
This placebo-controlled, double-blind study demonstrated
that oral administration of 2 g of vitamin C three times daily,
a water-soluble antioxidant, maintained the response of vaso-
dilation and the intracellular production of cGMP after sub-
lingual nitroglycerin during transdermal application of nitro-
glycerin in normal volunteers and in patients with IHD. These
findings suggest that oral supplementation of vitamin C may
prevent the development of nitrate tolerance during continu-
ous nitrate therapy.
Mechanisms of nitrate tolerance. Although the phenome-
non of nitrate tolerance was first described during the early
part of this century (15), it was not considered clinically
important (16) until later research demonstrated that nitrate
tolerance limited the efficacy of these drugs in patients with
IHD and congestive heart failure (17–19). The mechanism of
nitrate tolerance is multifactorial (3,18,20). Nitrate tolerance is
thought to be due to the inability of the vascular tissue to
respond to nitroglycerin (21). Mu¨nzel et al. (19) have proposed
Figure 4. Platelet cGMP levels before and after sublingual nitroglyc-
erin in normal volunteers (left) and patients with IHD (right). Data
shown are mean value 6 SEM. Symbols as in Figure 1. *p , 0.05
versus days 0 and 3.
Figure 5. Percent increase in platelet cGMP levels
after sublingual nitroglycerin in normal volunteers
(left) and patients with IHD (right). Data shown are
mean value 6 SD. Symbols as in Figure 3. *p , 0.01
versus days 0 and 3.
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four possible mechanisms of nitrate tolerance after chronic
exposure: 1) desensitization of the target enzyme guanylate
cyclase (6); 2) an increase in phosphodiesterase activity (22); 3)
intracellular sulfhydryl group depletion (23); and 4) impaired
nitroglycerin biotransformation (24). They recently demon-
strated (8) that enhanced angiotensin-II activities resulted in
increased production of oxygen-derived radicals that inhibit
the dilator action of nitroglycerin-derived nitric oxide. Al-
though oxidative stress may inactivate the enzymes involved in
nitric oxide production after organic nitrate administration, it
is more likely that free radicals inactivate nitric oxide itself,
resulting in the formation of peroxynitrite and leading to
impaired cGMP production and nitrate tolerance.
Previous studies on prevention of nitrate tolerance. Be-
cause nitrate tolerance potentially limits the therapeutic effi-
cacy of nitrates, there has been an extensive effort to develop
effective strategies to prevent this phenomenon.
Some studies have found that the concomitant administra-
tion of angiotensin-converting enzyme inhibitors and nitroglyc-
erin reversed or prevented nitrate tolerance (25–27), but other
studies failed to confirm these results (28,29). Although it is
difficult to explain the different efficacy of angiotensin-
converting enzyme inhibitors in these studies, the use of higher
doses of angiotensin-converting enzyme inhibitors may be
needed to inhibit angiotensin-II formation. Mu¨nzel and Bas-
senge (30) reported that high dose enalapril reversed nitrate
tolerance in vivo. These previous studies did not evaluate the
intracellular production of cGMP. Therefore, more informa-
tion is needed to determine the clinical usefulness of
angiotensin-converting enzyme inhibitors and diuretic drugs in
the prevention of nitrate tolerance.
In a recent study, Gogia et al. (31) demonstrated prevention
of nitrate tolerance with the concomitant use of hydralazine in
patients with chronic heart failure. Bauer and Fung (32) also
demonstrated prevention of nitrate tolerance with concurrent
administration of hydralazine in a rat model of congestive
heart failure. Those studies suggested prevention of the
nitrate-mediated decrease in renal blood flow and neurohor-
monal stimulation as a possible explanation for prevention of
nitrate tolerance. Elkayam (33) more recently reported that in
in vitro studies, hydralazine, by virtue of its antioxidant effect,
may prevent the nitrate-mediated formation of vascular super-
oxide and thus may prevent nitrate tolerance.
The effect of vitamin C on nitrate tolerance. Ascorbate or
vitamin C is the main water-soluble antioxidant in human
plasma (34). It effectively scavenges superoxide and other
reactive oxygen species and plays an important role in the
regulation of intracellular redox state through its interaction
with glutathione (35). Several large epidemiologic studies have
suggested that dietary intake of vitamin C and plasma vitamin
C concentration are inversely associated with the risk of IHD
(36–38). Recently, vitamin C has been reported to reverse
endothelial vasomotor dysfunction in the brachial circulation
of patients with coronary artery disease (39) and to improve
endothelial dysfunction in chronic smokers (40). We reported
the preventive effects of intravenous administration of ascor-
bate on nitrate tolerance in hemodynamic function and plate-
let cGMP level in patients with congestive heart failure (11). In
an experimental study, Bassenge and Fink (41) demonstrated
that vitamin C prevented nitrate tolerance in the dilation of the
coronary artery and the production of platelet cGMP. We
demonstrated in the present study that oral supplementation
of vitamin C, an antioxidant, prevented the attenuation of the
vasodilatory response and the intracellular production of
cGMP after administration of sublingual nitroglycerin during
continuous transdermal application of nitroglycerin. The
present study was performed using the same protocol as our
previous study on vitamin E. In our previous study, we
demonstrated the preventive effect of vitamin E on nitrate
tolerance in normal volunteers and patients with IHD (12).
These findings strongly support the theory that increased
production and activity of oxygen-derived free radicals contrib-
ute to the development of nitrate tolerance in patients who
receive long-term therapy with organic nitrate. On the basis of
these findings, oral supplementation of antioxidants may be an
effective treatment in patients with coronary artery disease, not
only for the secondary prevention of coronary artery disease,
but also for the prevention of nitrate tolerance in patients with
coronary artery disease receiving continuous nitrate therapy.
Study limitations. There are some limitations in the
present study:
1. We measured platelet cGMP levels to evaluate the
intracellular production of cGMP. The in vivo effects of
nitroglycerin on the intracellular production of cGMP in the
vascular smooth muscle cells can be evaluated only in biopsy
samples. In a previous study (13), we demonstrated that
platelet cGMP levels can be used as an indicator of the effects
of nitroglycerin and the development of nitrate tolerance.
Nitroglycerin activates soluble guanylate cyclase in platelets,
and the increased levels of platelet cGMP inhibit platelet
adhesion (42). Platelets predominantly contain the soluble
guanylate cyclase (43,44). Therefore, platelets are an appro-
priate material for the clinical measurement of intracellular
cGMP. In the present study, we demonstrated lower platelet
cGMP levels at baseline in patients with IHD than in normal
volunteers. However, forearm blood flow at baseline or the
responses of forearm blood flow and platelet cGMP to sublin-
gual nitroglycerin were not different between normal volun-
teers and patients with IHD. We could not explain this
discrepancy in the present study. More studies will be needed
to elucidate this problem.
2. We did not compare the effects of other antioxidants such
as vitamin E and beta-carotene in the present study. Vitamin
C, vitamin E and beta-carotene may all favorably influence
cardiovascular risk, but there are several important differences
between these naturally occurring antioxidants. Vitamin C is
water soluble and is present in most body fluids; vitamin E and
beta-carotene are both lipid-soluble, and the concentrations of
these compounds in plasma and specific cellular compartments
differ. The primary antioxidant mechanisms of these antioxi-
dants are also distinct. Thus, the beneficial effects observed in
this study cannot necessarily be extrapolated to other antioxi-
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dants. Recently, we reported the preventive effect of vitamin E
on nitrate tolerance in our study performed using the same
protocol (12). Therefore, both water- and lipid-soluble antioxi-
dants may have a preventive effect on nitrate tolerance.
3. We did not measure plasma vitamin C levels or oxidative
stress or hemodynamic function in the present study. The
anti-ischemic efficacy and antianginal efficacy of vitamin C will
require a separate study.
4. The dose of vitamin C given in this study, 2 g three times
daily, is unusually high. In our preliminary study, low dose
intake of vitamin C had no preventive effects on nitrate
tolerance in this protocol (data not shown). In the present
study, there was no adverse effect in all subjects. However, high
dose vitamin C intake is known to induce an increase in the
production of oxidized lipid because of depletion of vitamin E
(45). Igarashi et al. (46) studied the effect of vitamin C on
vitamin E levels in blood and found a statistically significant
increase in the plasma vitamin E level in subjects receiving a
vitamin E and vitamin C diet for 6 weeks. Thus, alpha-
tocopherol may be regenerated by ascorbate not only from an
alpha-tocopheroxyl radical but also from 8a-hydropheroxy
alpha-tocopherones (47). Therefore, to prevent side effects,
low dose intake of vitamin C concomitantly with vitamin E
may be effective for the prevention of nitrate tolerance. We
need further studies to establish an appropriate dose of
vitamin C.
Conclusions. The present findings suggest that combina-
tion therapy with vitamin C is potentially useful for the
prevention of nitrate tolerance during continuous nitrate ther-
apy in patients with IHD. Further studies are needed to clarify
the possible beneficial effects of antioxidant supplementation
on the development of nitrate tolerance.
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